Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1990-9-4
pubmed:abstractText
Homogentisic acid (HGA) (50 mg/kg) was given orally to 22 obligate heterozygotes for hereditary tyrosinemia type 1 (HT) and to 11 controls. After 1 h the mean +/- standard error (SE) plasma level of HGA was 30.42 +/- 1.41 micrograms/ml in carriers and 19.29 +/- 1.62 in controls. Mean +/- SE fasting delta-amino-levulinate dehydratase (delta-ALD) was 40.05 +/- 1.79 m microM/min/g Hb in carriers, much lower than the 60.81 +/- 5.11 found in controls. After 3 h this difference in levels of delta-ALD remained, with mean +/- SE values of 25.70 +/- 2.89 m microM/min/g Hb in carriers, compared with 48.83 +/- 5.37 in controls. Three-hour mean +/- SE excretion of fumarylacetone "equivalent" [FAc] in urine in carriers, 51.597 +/- 5.580 micrograms/mg/creatinine, was significantly higher than the 27.941 +/- 5.916 in controls. Three-hour excretion of succinylacetone "equivalent" [SAc] was also significantly higher in the urine of carriers. FAc in 3-h urine was identified by thin-layer chromatography and confirmed by gas chromatography/mass spectrometry. Multivariate stepwise discriminant analysis showed that the inclusion order of significant variables was as follows: HGA levels at 1 hr, fasting level of delta-ALD, residual level of HGA at 3 h, and 3-h excretion of [FAc]. Non-significant variables were HGA tolerance, levels of delta-ALD at 3 h, sex, and 3-h excretion of [SAc].(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-13271329, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-13319328, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-270706, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-3473612, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-4000758, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-4017276, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-4064334, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-457661, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-4692831, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-4829425, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-5005890, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-5125319, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-5763606, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-6522148, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-6622096, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-6826727, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-7116642, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-7145846, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-7275988, http://linkedlifedata.com/resource/pubmed/commentcorrection/2378359-7296896
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0002-9297
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
329-37
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Oral loading of homogentisic acid in controls and in obligate heterozygotes for hereditary tyrosinemia type I.
pubmed:affiliation
Department of Genetic Medicine, Laval University Medical Centre, Ste-Foy, Quebec, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't